Haemonetics Surges 17%+ on Multi-Year Plasma Supply Deal with CSL Behring

The Quick Take

• Haemonetics (HAE) shares jumped over 17% after announcing a multi-year plasma supply agreement with CSL Behring.
• The deal secures Haemonetics' revenue visibility through its NexSys PCS plasma collection technology.
• CSL Behring's capacity expansion signals rising global immunoglobulin demand, benefiting the plasma equipment supply chain.

Haemonetics' 17% single-session surge reflects the market's valuation of long-duration revenue contracts in medical device manufacturing. The multi-year plasma collection agreement with CSL Behring—one of the world's largest plasma-derived medicine manufacturers—provides Haemonetics with a predictable utilization pipeline for its NexSys PCS devices. In plasma technology, installed-base agreements effectively lock in recurring revenue streams across device placements, consumables, and service contracts, which is why contract announcements of this type reliably produce sharp re-ratings.

CSL Behring's expansion reflects a structural tailwind: immunoglobulin and albumin therapies face supply shortages globally, and plasma collection infrastructure investment is accelerating across North America and Europe. Haemonetics benefits directly from this capex cycle, competing primarily with Terumo BCT. The plasma supply chain implications are also positive for other Haemonetics segments—the hospital-focused TEG and OrthoPAT blood management products benefit from operator confidence in the broader Haemonetics platform.

Watch for HAE's next quarterly earnings to confirm whether the CSL deal is converting to new placements and consumable revenue. The macro variable is global immunoglobulin pricing: if plasma protein therapy demand sustains its 8-10% CAGR trajectory, Haemonetics' installed-base utilization will outperform consensus models. Investors should watch for CSL's half-year guidance on plasma collection centre expansion timelines as a leading indicator.

Synthesized from 1 source.